mRNA-based – Page 4 – Communicable Diseases Research

Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination

Contents

Published on 2022-02-282022-10-28
Journal: Obstetrics and gynecology [Category] COVID-19, COVID19(2023년), SARS,

Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany

독일 성인 인구의 체액성 SARS-CoV-2 백신 반응의 비교 규모 및 지속성

Multicenter Study

Published on 2022-02-162022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] ACE2 binding analyzed antibodies antibody antibody persistence Antibody Response Antibody titre antibody titres booster Comparative concerning dose Efficacy explain focus Germany healthcare Healthcare workers heterologous prime-boost homologous immune protection immune response immune responses immunocompromised individual immunocompromised individuals increases in infected individual information longitudinal study mRNA vaccination mRNA vaccines mRNA-based Neutralizing peaked Population population-based study produced proportion protective immunity question RBD recent recipient recipients reduced response robust SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 infections second vaccination significantly higher specific antibodies subpopulation subpopulations titre triggered vaccination Vaccine vaccine-induced immune response vaccine-induced immune responses variants variants of concern vector-based vaccines while wild-type
[DOI] 10.3389/fimmu.2022.828053 PMC 바로가기 [Article Type] Multicenter Study

Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics

Review

Published on 2022-02-112022-10-28
Journal: Pharmaceutics [Category] COVID-19,

Significance of HLA Haplotypes in Two Patients with Subacute Thyroiditis Triggered by mRNA-Based COVID-19 Vaccine

Case Report

Published on 2022-02-112022-10-28
Journal: Vaccines [Category] COVID-19,

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals

NK 세포 빈도, 기능 및 BNT162b2 mRNA 항 SARS-CoV-2 예방 접종을 받은 건강하고 면역이 약한 개인에서 백신 결과와 상관 관계

Research Article

Published on 2022-02-082022-09-12
Journal: Molecular Medicine [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] adaptive immune responses anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies baseline BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 mRNA vaccine Cancer characterized clinical material clinical trial Course COVID-19 Day description Effect EudraCT frequencies Frequency healthy healthy individuals immune cells immune response immune responses Immunocompromised immunocompromised individual Immunocompromised patient Immunocompromised patients in healthy individual Innate immune cells Innate immunity mRNA mRNA vaccination mRNA vaccine mRNA-based NK cell NK cells NKG2C non-randomized Open-label outcome Peripheral blood Phenotypes positive correlation preserved Prospective clinical trial Registered Result SARS-CoV-2 supplementary material Trial registration vaccination Vaccine vaccine trial viral infections
[DOI] 10.1186/s10020-022-00443-2 PMC 바로가기 [Article Type] Research Article

Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination

항인지질항체 양성 환자의 항PF4 항체 생산은 코로나19 예방접종에 영향을 받지 않는다

Article

Published on 2022-02-012022-09-12
Journal: RMD Open [Category] MERS, 진단,

Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?

Apolipoprotein A-1에 대한 체액 반응의 유도제로서의 Anti-SARS-CoV-2 mRNA 백신?

Article

Published on 2022-02-012022-09-12
Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] AAA1 Affect anti-SARS-CoV-2 anti-SARS-CoV-2 mRNA vaccines anti-SARS-CoV-2 vaccine apolipoprotein A-1 association autoantibodies Autoimmune Autoimmune response baseline Biomarker collected components COVID-19 density first vaccination fraction healthy control healthy controls humoral IgG IgG level IgG response immunoassays individual individuals induce inducer injection lipoprotein Local median mRNA vaccine mRNA-based observé outcomes Patient patients Population populations Prognosis Protein protocol raised recipient retrieved rheumatoid arthritis SARS-CoV-2 second vaccination serology shown significant increase Symptom systemic translate vaccination were measured were recorded
[DOI] 10.1111/eci.13713 PMC 바로가기 [Article Type] Article

Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study

혈액 투석 환자에서 mRNA 기반 SARS-CoV-2 백신 1차 및 2차 접종 후 IgG 항체 수준의 시간 의존적 진화: 다기관 연구

Multicenter Study

Published on 2022-01-252022-09-12
Journal: Nephrology, dialysis, transplantation : official p [Category] SARS, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome Adverse Adverse reaction age albumin antibody antibody production BNT162b2 Clinical data Cohort coronavirus coronavirus disease COVID-19 demographic dialysis dose effective Efficacy event Evolution ferritin first dose Haemodialysis higher risk identify IgG antibody immune response Immunoglobulin immunologic response implementation independent predictor median Mild mRNA vaccine mRNA vaccines mRNA-based multicentre Odds ratio of BNT162b2 pandemic Patient patients physical activity Population predicted questionnaire reduced Registered retrieved risk factor Safe SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose Seroconversion Spike protein the SARS-CoV-2 threshold vaccination Vaccine vaccine doses
[DOI] 10.1093/ndt/gfab293 PMC 바로가기 [Article Type] Multicenter Study

Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination

mRNA 백신 접종 후 치명적인 코로나19 감염에 대한 중간 정도의 면역 반응

Immunology

Published on 2022-01-252022-09-11
Journal: Frontiers in Immunology [Category] 변종, 진단, 치료기술, 치료법, 치료제,

[키워드] Alpha Alpha variant Alpha VOC analyzed anti-SARS-CoV-2 vaccination Antibody titers antigenic target Breakthrough infection CD4+ CD4+ T-cell CD8+ T cell CD8+ T cells cellular Cohort COVID-19 COVID-19 disease detectable disease manifestation disease onset Disease progression donors Endemic fatal COVID-19 had no humoral immune response Humoral immunity Inclusion indicate individual moderate mounted mRNA mRNA-based Neutralizing antibodies Neutralizing antibody titer Patient reduced response resulting robust S-protein SARS-CoV-2 SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 variants T cells T-cell Response Trigger uninfected Vaccination strategy Vaccine vaccine breakthrough infection variant VoC VOCs wild type
[DOI] 10.3389/fimmu.2022.816220 PMC 바로가기 [Article Type] Immunology

Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

Article

Published on 2022-01-182022-10-28
Journal: Viruses [Category] COVID-19,